Referenser

  1. Global Tuberculosis Report 2023. Geneva: World Health Organization, 2023.

  2. Vårdprogram tuberkulos. Svenska Infektionsläkarföreningen; 2023. Available from: https://infektion.net/kunskap/vardprogram-tuberkulos/

  3. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705-18.

  4. Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, et al. Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. J Antimicrob Chemother. 2018;73(10):2838-45.

  5. WHO operational handbook on tuberculosis. Module 1: Prevention - Tuberculosis preventive treatment. World Health Organization. . 2020. Available from: https://iris.who.int/bitstream/handle/10665/331525/9789240002906-eng.pdf

  6. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3).

  7. Rekommendationer för preventiva insatser mot tuberkulos – Hälsokontroll, smittspårning och vaccination. Folkhälsomyndigheten; Revidering 5 (april 2022). Available from: https://www.folkhalsomyndigheten.se/publikationer-och-material/publikationsarkiv/r/rekommendationer-for-preventiva-insatser-mot-tuberkulos-halsokontroll-smittsparning-och-vaccination/

Föregående sida
Behandling

Nästa sida
Tillbaka till kapitlets första sida